Pain Relief and Anti-inflammatory Agents Medications are essential for managing diverse health conditions, providing relief from pain and inflammation associated with injuries, acute illnesses, or chronic diseases. Their purpose is straightforward: to alleviate pain and reduce inflammation by targeting specific pathways, offering essential relief to those experiencing discomfort. Whether addressing postoperative pain, managing arthritis, or aiding recovery from injuries, these medications play a crucial role in enhancing the quality of life for many.
Did you know?
The discovery of aspirin, one of the earliest pain relief medications, can be traced back to the willow
tree's bark. Ancient civilizations recognized its analgesic properties, paving the way for modern pain relief
medications.
Pharmgenity Health supplies and exports Pain Relief and Anti-inflammatory APIs including Aceclofenac, Diclofenac, Etodolac, Etoricoxib, Ketorolac, Lornoxicam, Mefenamic Acid, Meloxicam, Nimesulide, Piroxicam, Tolfenamic Acid and Salicylic Acid, acting as a manufacturer, supplier, distributor and exporter of pain relief and anti-inflammatory APIs from Mumbai, India.
| SN | Product Image | Product Name | CAS No | Molecular Formula | Molecular Weight (g/mol) | Mechanism of Action |
|---|---|---|---|---|---|---|
| 1 |  |
Aceclofenac | 89796-99-6 | C16H13C12NO4 | 354.20 | Inhibits Cox-1 and COX-2 enzymes to reduce Inflammation and pain |
| 2 |  |
Diclofenac | 15307-79-6 | C14H11Cl2NO2 | 296.15 | Inhibits COX-1 and COX-2 enzymes to reduce inflammation and pain |
| 3 |  |
Etodolac | 41340-25-4 | C17H21NO3 | 287.35 | Selectively inhibits COX-2 enzyme to reduce inflammation and pain |
| 4 |  |
Etoricoxib | 202409-33-4 | C18H15ClN2O2S | 358.84 | Selectively inhibits COX-2 enzyme to reduce inflammation and pain |
| 5 |  |
Ketorolac (Tablet/Inj) | 74103-06-3 | C15H13NO3 | 376.41 | Inhibits COX-1 and COX-2 enzymes to reduce inflammation and pain |
| 6 |  |
Lornoxicam | 70374-39-9 | C13H10N2O4S2 | 371.79 | Inhibits COX-1 and COX-2 enzymes to reduce inflammation and pain |
| 7 |  |
Mefenamic Acid | 61-68-7 | C15H15NO2 | 241.29 | Inhibits COX enzymes to reduce inflammation and pain |
| 8 |  |
Meloxicam | 71125-38-7 | C14H13N3O4S2 | 351.41 | Preferentially inhibits COX-2 enzyme to reduce inflammation and pain |
| 9 |  |
Nimesulide | 51803-78-2 | C13H12N2O5S | 308.31 | Selectively inhibits COX-2 enzyme to reduce inflammation and pain |
| 10 |  |
Piroxicam | 36322-90-4 | C15H13N3O4S | 331.35 | Inhibits COX-1 and COX-2 enzymes to reduce inflammation and pain |
| 11 |  |
Tolfenamic Acid | 13710-19-5 | C14H12NO2S | 261.27 | Inhibits COX enzymes to reduce inflammation and pain |
| 12 |  |
Salicylic Acid | 69-72-7 | C7H6O3 | 138.12 | Inhibits COX enzymes and has keratolytic properties |
Other products are available based on customer requirements.
Share your requirements and our team will get back to you with pricing, product documentation, and export support.
If the listed products don't precisely fit your requirements, we're ready to customize our offerings to meet your specific needs. Connect with us for a personalized quote.
Non-selective NSAIDs like Diclofenac and Ketorolac inhibit both COX-1 and COX-2 enzymes, providing effective pain relief but with potential gastrointestinal side effects due to COX-1 inhibition in the stomach lining. COX-2 selective inhibitors like Etoricoxib and Nimesulide preferentially target the COX-2 enzyme responsible for inflammation and pain, offering comparable efficacy with reduced gastric irritation, making them preferable for patients with history of peptic ulcers or GI sensitivity.
Lornoxicam is unique among NSAIDs due to its balanced inhibition of COX-1 and COX-2 with a short elimination half-life, providing rapid onset of analgesia while allowing quick clearance from the body. This makes it particularly suitable for acute pain conditions like renal colic, postoperative pain, and acute musculoskeletal pain where rapid relief is needed without prolonged systemic exposure. Its analgesic potency is comparable to opioids in certain pain models without the associated respiratory depression or addiction risk.
Yes, we can supply pain relief APIs with specifications tailored to different dosage forms. For oral solid dosage manufacturing, APIs are supplied with defined particle size distribution, flow properties, and compressibility parameters suitable for tablet compression or capsule filling. For topical gels and creams, we provide APIs with appropriate solubility profiles and particle size specifications that ensure uniform dispersion in semisolid bases. We work with customers to define the right specification profile for their specific formulation platform.
Each batch of pain relief API undergoes comprehensive pharmacopeial testing including assay potency by HPLC, identification by IR and HPLC retention time, related substances and degradation products profiling, residual solvent analysis by GC, heavy metals content, sulfated ash, loss on drying, specific optical rotation for chiral NSAIDs, and microbial enumeration tests. For specific APIs like Ketorolac and Etodolac, additional chiral purity testing is performed to ensure the correct enantiomeric composition critical for safety and efficacy.
We maintain comprehensive impurity profiles for all our NSAID APIs, tracking identified and unidentified impurities against ICH Q3A thresholds. Forced degradation studies are conducted under acidic, basic, oxidative, photolytic, and thermal stress conditions to characterize the degradation pathway of each API. Batch-to-batch impurity data is monitored using statistical process control to ensure consistency. This data is shared with customers through regulatory documentation packages to support their drug product filings and stability commitments.
Get in touch with our team for detailed product information, documentation, and export pricing.